



Cardio3 BioSciences To Present At Forthcoming BioEquity Europe 2009 Meeting

Presentation to include details of the pivotal trial for C-Cure®, Cardio3 BioSciences' second generation stem cell therapy for heart failure

Mont-Saint-Guibert, Belgium, 3 June, 2008 Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announces that its CEO Dr Christian Homsy will present a corporate overview at the forthcoming BioEquity Europe 2009 conference on June 9 at 16:00. The conference takes place at the Hilton Munich Park Hotel in Munich, Germany on June 9-10, 2009.

During his presentation, Dr. Homsy will provide an outline of the science behind C-Cure®, the Company's second-generation stem cell therapy for the treatment of heart failure, and an overview of the ongoing pivotal trials for the product.

C-Cure is draws on an unrivalled understanding of the fundamental science of heart cell development at the Mayo Clinic and within the Cardio3 BioSciences scientific in-house team. The product involves taking a patient's own bone marrow cells and through a proprietary culturing technology, gives rise to 'cardiopoietic' cells that can regenerate damaged heart muscle. Unlike previous cell therapies for this indication, C-Cure is designed to produce new autologous heart muscle cells which behave identically to those lost in infarction without carrying the risk of rejection.

The first patient was enrolled in March in a randomized, prospective, multi-center trial, designed to evaluate the safety and efficacy of C-Cure beyond optimal clinical care in patients with heart failure.

Cardio3 BioSciences was founded in 2007 by clinicians from the Cardiovascular Center in Aalst, Belgium with a vision of using a cell-based approach for the treatment of heart disease. The Company is led by a senior management team with extensive experience in developing and commercialising pharmaceutical and medical technologies. Cardio3 BioSciences raised €13.7 million in a Series B fundraising and from grant funding in March 2009.

***** END *****

CARDIO3 BIOSCIENCES S.A.

Axisiparc Business Center – Rue Edouard Belin 12 – 1435 Mont-Saint-Guibert – Belgium
Tel +32 (10) 39 41 00 – Fax +32 (10) 39 41 41 – Email info@c3bs.com – www.c3bs.com



For more information contact:

Cardio3 BioSciences

Dr Christian Homsy, CEO

Tel: +32 10 39 41 00

Mayra Beydoun, Brand & Communication
Manager

Tel : +32 10 39 41 00

mbeydoun@c3bs.com

www.c3bs.com

Citigate Dewe Rogerson

Chris Gardner//Nina Enegren

Tel : +44 (0) 207 638 9571

chris.gardner@citigatedr.co.uk

nina.enegren@citigatedr.co.uk

About Cardio3 BioSciences

Cardio3 BioSciences is a leading Belgian biotechnology company specialising in stem cell-based therapies for the treatment of cardiovascular disease. The Company's lead product, C-Cure, is a highly innovative approach to the treatment of heart failure, one of the world's most pressing unmet medical needs. Based on a strategy developed by Cardio3 BioSciences' founders and leveraging technology from Mayo Clinic, C-Cure allows the differentiation of a patient's own cells into 'cardiopoietic' cells which grow into new heart cells and repair heart muscle.

The Cardio3 BioSciences team has extensive experience in developing and commercialising new pharmaceutical products and medical technologies and the Company's strategy is to drive the clinical development of C-Cure and to market the product itself in major territories. Cardio3 BioSciences was founded in July 2007 and is based in Mont-Saint-Guibert in the Walloon region of Belgium.